Literature DB >> 26471394

CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery.

Azadeh Kheirolomoom1, Elizabeth S Ingham1, Lisa M Mahakian1, Sarah M Tam1, Matthew T Silvestrini1, Spencer K Tumbale1, Josquin Foiret1, Neil E Hubbard2, Alexander D Borowsky2, William J Murphy3, Katherine W Ferrara4.   

Abstract

Ultrasonic activation of nanoparticles provides the opportunity to deliver a large fraction of the injected dose to insonified tumors and produce a complete local response. Here, we evaluate whether the local and systemic response to chemotherapy can be enhanced by combining such a therapy with locally-administered CpG as an immune adjuvant. In order to create stable, activatable particles, a complex between copper and doxorubicin (CuDox) was created within temperature-sensitive liposomes. Whereas insonation of the CuDox liposomes alone has been shown to produce a complete response in murine breast cancer after 8 treatments of 6 mg/kg delivered over 4 weeks, combining this treatment with CpG resolved local cancers within 3 treatments delivered over 7 days. Further, contralateral tumors regressed as a result of the combined treatment, and survival was extended in systemic disease. In both the treated and contralateral tumor site, the combined treatment increased leukocytes and CD4+ and CD8+ T-effector cells and reduced myeloid-derived suppressor cells (MDSCs). Taken together, the results suggest that this combinatorial treatment significantly enhances the systemic efficacy of locally-activated nanotherapy.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CpG; Doxorubicin; Immunotherapy; Temperature-sensitive liposome; Ultrasound

Mesh:

Substances:

Year:  2015        PMID: 26471394      PMCID: PMC4688109          DOI: 10.1016/j.jconrel.2015.10.016

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  48 in total

1.  Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.

Authors:  Azadeh Kheirolomoom; Lisa M Mahakian; Chun-Yen Lai; Heather A Lindfors; Jai Woong Seo; Eric E Paoli; Katherine D Watson; Eric M Haynam; Elizabeth S Ingham; Li Xing; R Holland Cheng; Alexander D Borowsky; Robert D Cardiff; Katherine W Ferrara
Journal:  Mol Pharm       Date:  2010-12-06       Impact factor: 4.939

2.  Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia.

Authors:  Azadeh Kheirolomoom; Chun-Yen Lai; Sarah M Tam; Lisa M Mahakian; Elizabeth S Ingham; Katherine D Watson; Katherine W Ferrara
Journal:  J Control Release       Date:  2013-08-28       Impact factor: 9.776

Review 3.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Journal:  Semin Cancer Biol       Date:  2012-02-01       Impact factor: 15.707

Review 4.  Coordinated regulation of myeloid cells by tumours.

Authors:  Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Vincenzo Bronte
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

5.  Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction.

Authors:  Martijn H den Brok; Stefan Nierkens; Jori A Wagenaars; Theo J Ruers; Carla C Schrier; Eric O Rijke; Gosse J Adema
Journal:  Vaccine       Date:  2011-11-30       Impact factor: 3.641

6.  Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells.

Authors:  Stefan Nierkens; Martijn H den Brok; Zacharias Garcia; Susan Togher; Jori Wagenaars; Melissa Wassink; Louis Boon; Theo J Ruers; Carl G Figdor; Stephen P Schoenberger; Gosse J Adema; Edith M Janssen
Journal:  Cancer Res       Date:  2011-07-25       Impact factor: 12.701

7.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

8.  Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.

Authors:  Ashley A Manzoor; Lars H Lindner; Chelsea D Landon; Ji-Young Park; Andrew J Simnick; Matthew R Dreher; Shiva Das; Gabi Hanna; Won Park; Ashutosh Chilkoti; Gerben A Koning; Timo L M ten Hagen; David Needham; Mark W Dewhirst
Journal:  Cancer Res       Date:  2012-09-04       Impact factor: 12.701

Review 9.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.

Authors:  M J M Gooden; G H de Bock; N Leffers; T Daemen; H W Nijman
Journal:  Br J Cancer       Date:  2011-05-31       Impact factor: 7.640

10.  Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.

Authors:  Sofia R Gameiro; Jack P Higgins; Matthew R Dreher; David L Woods; Goutham Reddy; Bradford J Wood; Chandan Guha; James W Hodge
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more
  10 in total

1.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

2.  Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo.

Authors:  Jennifer C Wischhusen; Sayan Mullick Chowdhury; Taehwa Lee; Huaijun Wang; Sunitha Bachawal; Rammohan Devulapally; Rayhaneh Afjei; Uday Kumar Sukumar; Ramasamy Paulmurugan
Journal:  J Control Release       Date:  2020-01-29       Impact factor: 9.776

3.  Combining activatable nanodelivery with immunotherapy in a murine breast cancer model.

Authors:  Azadeh Kheirolomoom; Matthew T Silvestrini; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Spencer K Tumbale; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2019-04-09       Impact factor: 9.776

4.  Intracellular trafficking of a pH-responsive drug metal complex.

Authors:  Azadeh Kheirolomoom; Elizabeth S Ingham; Joel Commisso; Neveen Abushaban; Katherine W Ferrara
Journal:  J Control Release       Date:  2016-10-13       Impact factor: 9.776

5.  Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin.

Authors:  Brett Z Fite; Azadeh Kheirolomoom; Josquin L Foiret; Jai W Seo; Lisa M Mahakian; Elizabeth S Ingham; Sarah M Tam; Alexander D Borowsky; Fitz-Roy E Curry; Katherine W Ferrara
Journal:  J Control Release       Date:  2017-04-07       Impact factor: 9.776

6.  Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.

Authors:  Hua Zhang; Wei-Lun Tang; Azadeh Kheirolomoom; Brett Z Fite; Bo Wu; Kenneth Lau; Mo Baikoghli; Marina Nura Raie; Spencer K Tumbale; Josquin Foiret; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; R Holland Cheng; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2020-11-13       Impact factor: 9.776

7.  Open-source, small-animal magnetic resonance-guided focused ultrasound system.

Authors:  Megan E Poorman; Vandiver L Chaplin; Ken Wilkens; Mary D Dockery; Todd D Giorgio; William A Grissom; Charles F Caskey
Journal:  J Ther Ultrasound       Date:  2016-09-05

Review 8.  Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.

Authors:  Roger Gilabert-Oriol; Gemma M Ryan; Ada W Y Leung; Natalie S Firmino; Kevin L Bennewith; Marcel B Bally
Journal:  Int J Mol Sci       Date:  2018-09-26       Impact factor: 5.923

Review 9.  Utilization of metal or non-metal-based functional materials as efficient composites in cancer therapies.

Authors:  Xiaoxiao He; Shiyue Chen; Xiang Mao
Journal:  RSC Adv       Date:  2022-02-24       Impact factor: 3.361

Review 10.  Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities.

Authors:  Colleen T Curley; Natasha D Sheybani; Timothy N Bullock; Richard J Price
Journal:  Theranostics       Date:  2017-08-23       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.